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Abstract
Because evasion of apoptosis can cause radioresistance of glioblastoma, there is a need to design rational strategies
that counter apoptosis resistance. In the present study, we investigated the potential of targeting the antiapoptotic
protein XIAP for the radiosensitization of glioblastoma. Here, we report that small-molecule XIAP inhibitors signifi-
cantly enhance γ-irradiation–induced loss of viability and apoptosis and cooperate with γ-irradiation to suppress
clonogenic survival of glioblastoma cells. Analysis of molecular mechanisms reveals that XIAP inhibitors act in con-
cert with γ-irradiation to cause mitochondrial outer membrane permeabilization, caspase activation, and caspase-
dependent apoptosis. Importantly, XIAP inhibitors also sensitize primary cultured glioblastoma cells derived from
surgical specimens as well as glioblastoma-initiating stemlike cancer stem cells for γ-irradiation. In contrast, they
do not increase the toxicity of γ-irradiation on some nonmalignant cells of the central nervous system, including rat
neurons or glial cells, pointing to some tumor selectivity. In conclusion, by demonstrating for the first time that small-
molecule XIAP inhibitors increase the radiosensitivity of glioblastoma cells while sparing normal cells of the central
nervous system, our findings build the rationale for further (pre)clinical development of XIAP inhibitors in combination
with γ-irradiation in glioblastoma.
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Introduction
Glioblastoma is the most common primary brain tumor and a highly
aggressive malignancy with a very poor prognosis [1]. Despite intensive
treatment protocols, the resistance of glioblastoma to current regimens
including radiotherapy represents an ongoing challenge [2]. This high-
lights the need to develop novel approaches to overcome radioresistance
of glioblastoma to improve the dismal prognosis of this cancer [3].
Apoptosis is the cell’s intrinsic death program that controls normal
tissue homeostasis [4]. Apoptosis pathways can be initiated through
death receptors or mitochondria and usually results in activation of
caspases as common effector molecules [4]. Themitochondrial pathway
of apoptosis is engaged by the release of cytochrome c and second
mitochondria–derived activator of caspase (Smac)/direct IAP binding
protein with low pI (DIABLO) from mitochondria into the cytosol
[5,6]. Cytochrome c triggers caspase-3 activation through the formation
of the apoptosome complex, whereas Smac/DIABLO promotes apop-
tosis by neutralizing inhibitor of apoptosis (IAP) proteins [5].
Evasion of apoptosis is one of the hallmarks of human cancers in-
cluding glioblastoma [7]. Also, defects in apoptosis pathways contribute
to chemoresistance or radioresistance because therapy-induced cyto-
toxicity is mediated to a large extent by the induction of cell death
including apoptosis in cancer cells [8]. Apoptosis signaling may be
disrupted by the aberrant expression of antiapoptotic proteins [9]. For
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example, most human cancers harbor high levels of IAP proteins in-
cluding XIAP [10]. Aberrant expression of IAPs in tumor cells has
been associated with treatment resistance and dismal prognosis [10].
Therefore, therapeutic targeting of IAPs such as XIAP may offer new
possibilities to bypass resistance, for example, resistance to radiation-
induced cell death.
In a proof-of-concept study, we previously demonstrated that Smac
peptides, which antagonize XIAP, sensitize glioblastoma cells for
TRAIL-induced apoptosis in vitro and in vivo [11]. Further, we re-
ported that genetic inactivation of XIAP increases radiation-induced
apoptosis in neuroblastoma and pancreatic carcinoma cells [12,13].
To translate the concept of targeting XIAP for radiosensitization into
a clinically applicable approach to improve the efficacy of radiotherapy
in glioblastoma, in the present study, we evaluated the therapeutic
potential of small-molecule XIAP inhibitors for the radiosensitization
of glioblastoma.
Materials and Methods
Cell Culture and Reagents
Glioblastoma cell lines were obtained from the American Type
Culture Collection (Manassas, VA) and cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) or RPMI 1640 (Life Technologies,
Inc, Eggenstein, Germany) supplemented with 10% fetal calf serum
(FCS; Biochrom, Berlin, Germany), 1 mM glutamine (Biochrom),
1% penicillin/streptavidin (Biochrom), and 25 mM HEPES (Bio-
chrom) as described [14]. Primary cultured glioblastoma cells and
glioblastoma-initiating cells were cultured as described [14,15].
The study was approved by the Ethics Committee, Medical Faculty,
University of Ulm. Hippocampal rat neurons were prepared and
cultured as described [16], seeded at 5 × 104 cells/cm2 in 24-well
plates and irradiated on day 7. Rat glial cells from the cerebral cor-
tex were prepared and cultured as described [17] and seeded at 5 ×
104 cells/cm2 in 96-well plates after irradiation. Animal experiments
were performed in accordance with institutional and national regula-
tions; research protocols were approved by relevant authorities. XIAP
inhibitor 1, XIAP inhibitor 2, and control compound correspond to
compounds 2, 11, and 15, respectively, as described by Oost et al.
[18] and were kindly provided by IDUN Pharmaceuticals now Pfizer,
Inc (Groton, CT). XIAP inhibitors are capped tripeptides consisting
of unnatural amino acids that were designed on the basis of the nuclear
magnetic resonance structure of a Smac peptide bound to the BIR3
domain of XIAP and bound to XIAP BIR3 with high nanomolar af-
finities [18]. A close structural analog that weakly binds to XIAP served
as control [18]. All chemicals were purchased by Sigma (Deisenhofen,
Germany) unless indicated otherwise.
Determination of Apoptosis, Cell Viability, and
Clonogenic Survival
Cells were treated with γ-irradiation (Cs-137, 44 Tbq, 4 Gy/min;
Nuclear Data, Frankfurt, Germany) at indicated doses and incubated
for the indicated times in the presence of XIAP inhibitors, control com-
pound, or solvent without replenishment of medium or XIAP inhibi-
tors. Apoptosis was determined by fluorescence-activated cell-sorting
analysis (FACScan; BD Biosciences, Heidelberg, Germany) of DNA
fragmentation of propidium iodide–stained nuclei as described [19].
The percentage of specific apoptosis is calculated as follows: 100 ×
[(experimental apoptosis − spontaneous apoptosis)/(100 − spontaneous
apoptosis)]. Spontaneous apoptosis refers to the rate of apoptosis of
untreated cells. Cell viability was assessed by MTT assay according
to themanufacturer’s instructions (RocheDiagnostics,Mannheim,Ger-
many). For clonogenic assay, cells were seeded at 0.017 × 103 cells/cm2
after irradiation, and colony formation after 3 weeks was assessed by
crystal violet staining (0.75% crystal violet, 50% ethanol, 0.25%NaCl,
1.57% formaldehyde).
Determination of Mitochondrial Membrane Potential
and Cytochrome c Release
CMXRos (1 μM; Molecular Probes, Karlsruhe, Germany) was used
to measure the mitochondrial transmembrane potential. Cells were in-
cubated for 30 minutes at 37°C in the presence of the fluorochrome
and immediately analyzed by flow cytometry. Cytochrome c release
was determined in permeabilized cells using mouse anti–cytochrome
c monoclonal antibody (BD Biosciences) as described [20].
Western Blot Analysis
Western blot analysis was performed as described previously [14]
using the following antibodies: mouse anti–caspase-8 (ApoTech Corp,
Epalinges, Switzerland); rabbit anti–caspase-3 (Cell Signaling, Beverly,
MA); rabbit anti–caspase-9 and mouse anti-XIAP (BD Biosciences);
rabbit anti-cIAP2, goat anti-cIAP1, and rabbit antisurvivin (R&D Sys-
tems, Inc, Wiesbaden, Germany); or mouse anti–β-actin (Sigma) fol-
lowed by goat-antimouse or goat-antirabbit immunoglobulin G (IgG)
conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Santa
Cruz, CA). Enhanced chemiluminescence was used for detection
(Amersham Bioscience, Freiburg, Germany).
Caspase Activity
Caspase activity was determined in living nonfixed nonlysed cells as
described [13] using a caspase-3 substrate conjugated to rhodamine
R110 (N -benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone-
R110 [zDEVD-R110]) from Molecular Probes. The broad-range cas-
pase inhibitor zVAD.fmk (Bachem, Heidelberg, Germany) was used for
the inhibition of caspases.
Immunohistochemistry
For immunohistochemical staining, cells were seeded on poly-L-
lysine–coated coverslips (Karl Hecht KG, Sondheim, Germany), in-
cubated for 3 hours at 37°C, and stained with mouse anti-CD133/1
antibody (1:10; Miltneyi Biotec, Bergisch Gladbach, Germany) ac-
cording to the manufacturer’s instructions. For nestin staining, cells
were fixed for 10 minutes with 4% paraformaldehyde, incubated for
30 minutes with blocking buffer (2% BSA, 0.1% horse serum, and
0.1% Triton X-100), and stained with mouse anti–nestin antibody
(1:100; Chemicon, Schwalbach, Germany) overnight at 4°C followed
by staining with goat–antimouse IgG–fluorescein isothiocyanate anti-
body (1:1000; Chemicon) and 4′-6-diamidino-2-phenylindole. Slides
were mounted using Vecta shield mounting medium (Vector Labo-
ratories, Burlingame, CA). Negative controls were performed by
omitting the first step with primary antibody and yielded negative re-
sults. Slides were analyzed using an immunofluorescence microscope
(Olympus, Hamburg, Germany).
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Figure 1. XIAP inhibitors enhance γ-irradiation–induced apoptosis in glioblastoma cells. (A and B) Glioblastoma cells were treated for the
indicated times with 10 Gy of γ-irradiation (A) or for 144 hours with indicated doses of γ-irradiation and/or 10 μM XIAP inhibitors, control
compound, or solvent (B). Cell viability was determined by MTT assay and expressed as a percentage of untreated controls. (C) A172 cells
were treated for 144 hours with indicated doses of γ-irradiation and/or 10 μM XIAP inhibitors, control compound, or solvent. Apoptosis was
determined by FACS analysis of DNA fragmentation of propidium iodide–stained nuclei. (D) Clonogenic survival after treatment with 3 Gy of
γ-irradiation and/or 10 μMXIAP inhibitor 2, control compound, or DMSOwas assessed by crystal violet staining. A representative experiment
of three independent experiments is shown. InA toC,mean±SEMof three independent experiments performed in triplicate are shown;#P<
.05, *P< .01, comparing XIAP inhibitors with solvent (signs above graphs are for XIAP inhibitor 1, signs below graphs are for XIAP inhibitor 2).
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Statistical Analysis
Statistical significance was assessed by Student’s t test using Winstat
software (R. Fitch Software, Bad Krozingen, Germany).
Results
Sensitization of Glioblastoma Cells for γ-Irradiation–Induced
Apoptosis by XIAP Inhibitors
To explore the therapeutic potential of small-molecule XIAP inhibi-
tors for the radiosensitization of glioblastoma, we selected the glioblas-
toma cell lines U87MG, A172, T98G, and U118MG, which all harbor
PTEN mutation and are p53 wild type (U87MG and A172) or p53
mutant (T98G and U118MG) [21]. We used small-molecule XIAP in-
hibitors that were designed against the BIR3 domain of XIAP based on
the nuclear magnetic resonance structure of a Smac peptide bound to
XIAP BIR3 [18]. A close structural analog that weakly binds to XIAP
served as a control [18]. First, we investigated the effects of XIAP in-
hibitors as single agents on cell viability of glioblastoma cells. XIAP in-
hibitors exerted no detectable effect on cell viability of glioblastoma
cells even upon prolonged treatment for 144 hours (Figure W1).
Next, we tested the effect of XIAP inhibitors in combination with
γ-irradiation in glioblastoma cells. Importantly, XIAP inhibitors sig-
nificantly enhancedγ-irradiation–induced loss of viability in a time- and
dose-dependent manner (Figure 1, A and B). By comparison, glioblas-
toma cells displayed low sensitivity to γ-irradiation alone, in line with
previous findings [22]. These results demonstrate that inhibition of
XIAP by small-molecule inhibitors radiosensitizes glioblastoma cells.
To examine radiosensitization of glioblastoma cells by XIAP in-
hibitors in more detail, we selected A172 glioblastoma cells because
γ-irradiation–induced cytotoxicity was strongly enhanced in these
cells in the presence of XIAP inhibitors. Analysis of DNA fragmen-
tation as a characteristic feature of apoptotic cell death showed that
XIAP inhibitors significantly increased γ-irradiation–induced apoptosis
(Figure 1C). The control compound slightly enhanced γ-irradiation–
induced apoptosis (Figure 1C), consistent with its strongly reduced abil-
ity to bind to the BIR3 domain of XIAP [18]. To investigate whether
inhibition of XIAP also affects long-term survival after γ-irradiation,
we performed colony assays. Notably, XIAP inhibitors cooperated with
γ-irradiation to suppress colony formation showing that they also act
in concert with γ-irradiation to reduce long-term survival (Figure 1D).
Together, this set of experiments demonstrates that XIAP inhibitors
cooperate with γ-irradiation to induce apoptosis and to suppress clono-
genic growth of glioblastoma cells.
XIAP Inhibitors Enhance γ-Irradiation–Induced Caspase
Activation and Mitochondrial Perturbations
Next, we investigated possible molecular mechanisms that mediate
the synergistic action of XIAP inhibitors andγ-irradiation. Because XIAP
inhibitors 1 and 2 showed similar activities to enhance γ-irradiation–
induced apoptosis (Figure 1), we used XIAP inhibitor 2 for these studies.
To explore the involvement of caspases, we assessed activation of the
caspase cascade by Western blot analysis. XIAP inhibitor 2 enhanced
γ-irradiation–induced cleavage of caspase-3 and caspase-8 into active
cleavage fragments (Figure 2A). To examine whether the increased cleav-
age of caspase-3 also translates into enhanced enzymatic caspase activity,
we performed caspase activity assays. Similarly, XIAP inhibitor 2 signifi-
cantly increased γ-irradiation–induced caspase-3 activity compared with
cells that were exposed to γ-irradiation in the absence of the XIAP inhib-
itor (Figure 2B). To test whether caspase activity was required for apop-
tosis induction, we used the broad-range caspase inhibitor zVAD.fmk.
Importantly, apoptosis in response to the combination treatment with
XIAP inhibitor 2 and γ-irradiation was significantly reduced in the pres-
ence of zVAD.fmk, demonstrating that apoptosis occurred in a caspase-
dependent manner (Figure 2 C).
To investigate whether inhibition of XIAP affects the mitochondrial
pathway of apoptosis upon γ-irradiation, we assessed mitochondrial
membrane potential and cytochrome c release. Interestingly, XIAP
inhibitor 2 significantly increased γ-irradiation–induced loss of mito-
chondrial membrane potential and cytochrome c release frommitochon-
dria in a time-dependent manner (Figure 3). Together, these findings
show that inhibition of XIAP enhances γ-irradiation–induced caspase
activation and mitochondrial perturbations in glioblastoma cells.
No Cytotoxicity of XIAP Inhibitors in Combination with
γ-Irradiation on Nonmalignant Central Nervous System Cells
Furthermore, we examined the effect of XIAP inhibitors on normal
cells of the central nervous system to test for potential toxic effects.
Notably, treatment with XIAP inhibitors as single agents did not alter
cell viability of rat neurons or rat glial cells (Figures 4 and W3). In ad-
dition, XIAP inhibitors did not increase the sensitivity of these cells
toward γ-irradiation (Figures 4 and W3). By comparison, XIAP inhib-
itors and γ-irradiation showed cross-species activity against rat glio-
blastoma cells (data not shown), further supporting the notion that
XIAP inhibitors preferentially sensitize malignant over nonmalignant
cells to γ-irradiation. These data demonstrate that XIAP inhibitors
do not exert detectable toxicity on some normal cells of the central
nervous system and also do not enhance the toxicity of γ-irradiation
on these nonmalignant cells at concentrations that sensitize glioblastoma
cells for γ-irradiation.
Figure 1. (continued)
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Figure 2. XIAP inhibitor enhances γ-irradiation–induced activation of caspases. (A and B) A172 cells were treated with 10 Gy of γ-irradiation
and/or 10 μM XIAP inhibitor 2, control compound, or DMSO for the indicated times. Caspase activation was assessed by Western blot
analysis (A) and caspase activity was assessed by FACS analysis using rhodamine-conjugated caspase-3 substrate zDEVD-R110 (B); fold
induction in caspase-3 activity is shown. (C) A172 cells were treated with 10 Gy of γ-irradiation and/or 10 μM XIAP inhibitor 2, control com-
pound, or DMSO for 144 hours in the presence or absence of 25 μM zVAD.fmk. Apoptosis was determined by FACS analysis of DNA
fragmentation of propidium iodide–stained nuclei. Means ± SEM of three independent experiments performed in triplicate are shown;
*P < .01 comparing XIAP inhibitor with solvent.
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XIAP Inhibitors Sensitize Primary Cultured Glioblastoma
Cells and Glioblastoma-Initiating Cells for γ-Irradiation
To test the potential clinical relevance of our findings, we extended
our studies to primary cultured glioblastoma samples obtained from
surgical specimens, which we previously characterized [14]. Primary
cultured glioblastoma cells expressed considerable levels of IAP proteins,
including XIAP, cIAP1, cIAP2, and survivin, with the exception of GB2,
which displayed low levels of survivin (Figure 5A). Importantly, XIAP
inhibitors significantly increased γ-irradiation–induced loss of viability
also in primary cultured glioblastoma cells (Figure 5B). In addition,
XIAP inhibitors acted in concert with γ-irradiation to trigger apoptosis,
loss of mitochondrial membrane potential, and caspase activation in
these cells (Figure 5, C–E).
Because glioblastoma stem cells have recently been linked to radio-
resistance [23,24], we then explored whether XIAP inhibitors modu-
late the sensitivity of these tumor-initiating cancer stem cells toward
γ-irradiation. Glioblastoma-initiating cells were isolated from clinical
samples and have been previously described and characterized [15].
Expression of the stem cell markers nestin and CD133, neurosphere
formation, and differentiation into neuronal and glial lineages as pa-
rameters of glioblastoma-initiating cells are shown (Figures 6A and
W2). Analysis of IAP expression showed that cIAP2 and XIAP pro-
tein were expressed in both glioblastoma-initiating cell lines, whereas
cIAP1 and survivin were detectable at much higher levels in one of
the glioblastoma-initiating cell lines (Figure 6B). Intriguingly, XIAP
inhibitor 2, but not the control compound, significantly reduced cell
viability of glioblastoma-initiating cells upon γ-irradiation (Figure 6,
C and D). This set of experiments demonstrates that XIAP inhibitors
sensitize primary cultured glioblastoma cells as well as glioblastoma-
initiating cells for γ-irradiation.
Discussion
Because defects in apoptosis programs, for example, high expression
of antiapoptotic molecules, can cause resistance to treatment regimens
Figure 3. XIAP inhibitor enhances γ-irradiation–induced mitochon-
drial perturbations. Glioblastoma cells were treated with 10 Gy of
γ-irradiation and/or 10 μM XIAP inhibitor 2, control compound, or
DMSO for the indicated times. Mitochondrial membrane potential
(MMP; A) and cytochrome c release (B) were assessed by FACS
analysis. Means ± SEM of three independent experiments per-
formed in triplicate are shown; *P < .01 comparing XIAP inhibitor
with solvent (signs above graphs are for XIAP inhibitor 1, signs below
graphs are for XIAP inhibitor 2).
Figure 4. Effect of XIAP inhibitors in combination with γ-irradiation
on nonmalignant central nervous system cells. Rat neurons (A) and
rat glial cells (B) were treated with 5 Gy of γ-irradiation and/or 10 μM
XIAP inhibitor 2, control compound, or DMSO for 144 hours. Cell
viability was determined by MTT assay and expressed as a percent-
age of untreated controls. Means ± SEM of three independent ex-
periments performed in triplicate are shown.
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Figure 5. XIAP inhibitors sensitize primary cultured glioblastoma cells for γ-irradiation. (A) Protein expression of XIAP, cIAP1, cIAP2, and
survivin were assessed in primary cultured glioblastoma cells (GB1, GB2, and GB3) by Western blot analysis; β-actin was used as loading
control. (B) Primary cultured glioblastoma cells were treated with 10 Gy of γ-irradiation and/or 10 μM XIAP inhibitors, control compound, or
DMSO for the indicated times. Cell viability was determined by MTT assay and expressed as a percentage of untreated controls. (C–E)
Primary cultured glioblastoma cells were treated with indicated doses of γ-irradiation and/or 10 μM XIAP inhibitors, control compound,
or DMSO for 144 hours (C), 96 hours (E), or indicated time points (D). Apoptosis was determined by FACS analysis of DNA fragmentation
of propidium iodide–stained nuclei (C), loss of mitochondrial membrane potential by flow cytometry (E), and caspase activation by Western
blot analysis (D). In B and C, mean ± SEM of three independent experiments performed in triplicate are shown; *P < .01 comparing XIAP
inhibitor with solvent (signs above graphs are for XIAP inhibitor 1, signs below graphs are for XIAP inhibitor 2).
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Figure 6. XIAP inhibitors sensitize glioblastoma-initiating cells for γ-irradiation. (A and B) Glioblastoma-initiating cells (BTSC1 and BTSC2)
were analyzed for nestin and CD133 expression by immunohistochemistry (A, original magnifications: upper panels, ×60; middle and lower
panels, ×40). Sphere-forming ability was analyzed by culture in neural stem cell medium (A, original magnification, ×10). The expression of
XIAP, cIAP1, cIAP2, and survivin was determined by Western blot analysis (B). (C and D) Glioblastoma-initiating cells (C, BTSC1; D, BTSC2)
were treated with the indicated doses of γ-irradiation and/or 10 μM XIAP inhibitors, control compound, or DMSO for 120 hours (left panels)
or 168 hours (right panels). Cell viability was determined byMTT assay and expressed as a percentage of untreated controls. Means ± SEM
of three independent experiments performed in triplicate are shown; *P < .01 comparing XIAP inhibitor with solvent.
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including radiotherapy [25,26], current attempts to improve the out-
come of glioblastoma patients depend on strategies to overcome apop-
tosis resistance. In the present study, for the first time, we provide evidence
that inhibition of the antiapoptotic protein XIAP by small-molecule
inhibitors is a novel and effective approach for the radiosensitization
of glioblastoma. This conclusion is supported by several independent
pieces of evidence. First, small-molecule XIAP inhibitors significantly
enhance γ-irradiation–induced cytotoxicity and apoptosis and cooper-
ate with γ-irradiation to suppress clonogenic survival of glioblastoma
cell lines. Mechanistic studies reveal that XIAP inhibitors act in con-
cert with γ-irradiation to enhance caspase activation and mitochon-
drial outer membrane permeabilization. Second, XIAP inhibitors
also increase the sensitivity to γ-irradiation in glioblastoma-initiating
cells and in primary cultured glioblastoma cells derived from surgical
specimens, further underscoring the clinical relevance of the find-
ings. Third, XIAP inhibitors do not enhance the toxicity ofγ-irradiation
on some nonmalignant cells of the central nervous system, including
neurons and glial cells, at concentrations that sensitize glioblastoma
cells to γ-irradiation. Together, these findings indicate that inhibi-
tion of XIAP by small-molecule inhibitors is a promising strategy to
enhance the radiosensitivity of glioblastoma cells with little effect on
normal cells of the central nervous system, thus pointing to a therapeu-
tic window.
Our findings have several important implications. First, novel ap-
proaches to increase the responsiveness of glioblastoma to current
treatment modalities such as radiation open new perspectives for
more effective therapeutic options for glioblastoma patients and
may ultimately affect patients’ survival. Although radiotherapy is one
mainstay of glioma therapy, resistance to radiotherapy still presents
an unsolved clinical problem [3]. This highlights the need to design
innovative strategies to potentiate the efficacy of radiotherapy. Increas-
ing evidence suggests that high expression levels of XIAP are associated
with a reduced response to irradiation in several types of cancers, for
example, neuroblastoma, pancreatic carcinoma, and lung cancer [12,
13,27,28]. Thus, one approach to increase the efficacy of radiotherapy
is based on the concept that intact apoptosis signaling pathways are
crucial for mediating the antitumor effects of radiotherapy. In line with
this notion, our results demonstrate that the neutralization of the anti-
apoptotic function of XIAP by small-molecule inhibitors enhances the
antitumor cytotoxicity of γ-irradiation. The clinical relevance of this
strategy is highlighted by the fact that XIAP inhibitors cooperate with
γ-irradiation to induce apoptosis not only in glioblastoma cell lines but
also in primary cultured glioblastoma cells. Although our study is the
first to demonstrate that small-molecule XIAP inhibitors cooperate with
γ-irradiation in glioblastoma, our group and other investigators have
previously reported that pharmacological inhibition of XIAP enhance
radiosensitivity in pancreatic, lung, and breast carcinoma [13,27,29,
30]. This points to a broader relevance of the concept to use XIAP in-
hibitors for the radiosensitization of human cancers.
Second, XIAP inhibitors are also effective to increase the radiosensi-
tivity of glioblastoma-initiating cells. Because it is in particular the
cancer stem cell population that is considered to confer radioresistance
in glioblastoma [16,23,24], strategies that also target this rare yet highly
malignant population in glioblastoma are of foremost relevance.
Whereas the preferential activation of the DNA damage response in
glioblastoma stem cells has been implied in the resistance to irradiation
[23], the molecular mechanisms of radioresistance of glioblastoma stem
cells have not exactly been identified. Irrespective of the primary mech-
anisms of radioresistance of glioblastoma stem cells, our findings dem-
onstrate that enhanced activation of apoptosis effector programs upon
irradiation by inhibition of XIAP can increase the radiosensitivity of
glioblastoma-initiating cells.
Third, it is feasible that our approach can be translated into clinical
application because small-molecule XIAP inhibitors have recently en-
tered clinical trials and are currently evaluated as single agents [10,31].
Therefore, it is a timely question to develop rational XIAP inhibitor–
based combination regimens with cooperative antitumor activity for
the future clinical development of XIAP inhibitors.
Fourth, the apparent lack of toxicity of XIAP inhibitors alone and
in combination with γ-irradiation on some normal cells of the central
nervous system at concentrations of XIAP inhibitors that sensitize glio-
blastoma cells to γ-irradiation points to a therapeutic index that could
be exploited for preferential radiosensitization of malignant versus non-
malignant cells. The identification of the underlying mechanism(s) that
are responsible for this differential sensitivity to XIAP inhibitors re-
mains subject to future investigations.
Clinically, resistance to apoptosis is a major cause of treatment fail-
ure in glioblastoma [32]. In a clinical perspective, our findings pro-
vide the rationale for further (pre)clinical development of XIAP
inhibitors in combination with γ-irradiation to increase the radiosen-
sitivity of glioblastoma.
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Figure W1. Effect of XIAP inhibitors on glioblastoma cells. Glioblastoma cells were treated for 144 hours with the indicated concentrations
of XIAP inhibitors, control compound, or solvent. Cell viability was determined by MTT assay and expressed as a percentage of untreated
controls. Means ± SEM of three independent experiments performed in triplicate are shown.
Figure W2. Differentiation of glioblastoma-initiating cells into neuronal and glial lineages. Glioblastoma-initiating cells (BTSC1 and BTSC2)
were differentiated for 2 weeks. Neuronal and glial lineages were assessed by immunofluorescent staining of microtubule-associated pro-
tein 2 (MAP2) and glial fibrillary acidic protein (GFAP), respectively. For GFAP staining, cells were plated in chamber slides (BD Falcon; BD
Biosciences) and were cultivated in DMEM supplemented with 10% heat-inactivated FCS, 10 mM HEPES, and 2 mM L-glutamine for
2 weeks. Cells were fixed with 4% PFA for 10 minutes, blocked with blocking buffer (2% BSA, 0.1% horse serum, and 0.1% Triton X-100)
for 30minutes, and stained with primary rabbit anti–GFAP antibody (1:200; Promega, Madison,WI) overnight at 4°C followed by staining with
anti-rabbit IgG–Texas Red secondary antibody and staining with DAPI. For MAP2 staining, cells were plated on coverslips coated with poly-
L-lysine and cultured in DMEM supplemented with 10% heat-inactivated FCS, 10 mM HEPES, and 2 mM L-glutamine overnight, and DMEM
medium was exchanged with neurobasal medium (Invitrogen, Karlsruhe, Germany) supplemented with B-27 containing vitamin A (Gibco,
Karlsruhe, Germany), 100 U/ml penicillin/streptomycin, 10 mM HEPES, and 2 mM L-glutamine for 2 weeks. Cells were fixed with 4% PFA
for 10 minutes, blocked with blocking buffer (2% BSA, 0.1% horse serum, and 0.1% Triton X-100) for 30 minutes, and stained with primary
rabbit anti-MAP2 antibody (1:50; Cell Signaling) overnight at 4°C followed by staining with goat anti-rabbit IgG–Texas Red secondary antibody
(Vector Laboratories) and staining with DAPI. Slides were mounted using Vecta shield mounting medium (Vector Laboratories). Slides were
analyzed using an immunofluorescencemicroscope (Olympus).MAP2 staining could not beperformed in BTSC2 cells because these cells did
not adhere to coverslips in neurobasal medium, possibly because they lack caspase-8 protein expression, which has been implicated in cell
adhesion (Senft J, Helfer B, and Frisch SM (2007). Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell
adhesion and motility. Cancer Res 67, 11505–9).
Figure W3. Effect of XIAP inhibitors in combination with γ-irradiation on glial cells. Rat neurons glial cells were treated with 10 Gy of
γ-irradiation and/or 10 μM XIAP inhibitor 2, control compound, or DMSO for 144 hours. Cell viability was determined by MTT assay and
expressed as a percentage of untreated controls. Means ± SEM of three independent experiments performed in triplicate are shown.
